Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma

British Journal of Cancer

Volumn 113, Issue 4, 2015, Pages 616-625

  Yu, H ^a,b   Liu, R ^b   Ma, B ^b   Li, X ^b   Yen, H Y ^b   Zhou, Y ^b   Krasnoperov, V ^c   Xia, Z ^a   Zhang, X ^a,b   Bove, A M ^d   Buscarini, M ^d   Parekh, D ^b   Gill, I S ^e   Liao, Q ^a   Tretiakova, M ^f   Quinn, D ^b   Zhao, J ^a   Gill, P S ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Vasgene Therapeutics Inc   (United States)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Axl; monoclonal antibody; renal cell carcinoma; targeted therapy

Indexed keywords

HUMANIZED MONOCLONAL ANTIBODY 173; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE AXL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; ONCOPROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER SIZE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; EMBRYO CELL; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RENAL CANCER CELL LINE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL MOTION; CELL SURVIVAL; HEK293 CELL LINE; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; HEK293 CELLS; HT29 CELLS; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84939262957     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.237     Document Type: Article

References (45)

1. Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S. (2013). Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 122(14): 2443-2452.
2. Bosurgi L, Bernink JH, Delgado Cuevas V, Gagliani N, Joannas L, Schmid ET, Booth CJ, Ghosh S, Rothlin CV. (2013). Paradoxical role of the protooncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci USA. 110(32): 13091-13096.
3. Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. (2003). Expression of the proto-oncongene Axl in renal carcinoma. DNA Cell Biol. 22(8): 553-40.
4. Collett GD, Sage AP, Kirton JP, Alexander MY, Gilmore AP, Canfield AE. (2007). Axl/phosphatidylinositol3-kinase signaling inhibits mineral deposition by vascular smooth muscle cells. Circ Res. 100(4): 502-509.
5. Deschavanne PJ, Fertil B. (1996). A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys. 34: 251-266.
6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, ShanM, Simantov R, Bukowski RM. TARGET Study Group. (2007). Sorafenib in Advanced Clear-cell Renal-cell Carcinoma. N Engl J Med. 356(2): 125-134.
7. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 370: 2103-2111.
8. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, Spizz G, Varnum B, Der C, Liu ET. (1996). Differential activation of the Ras/extracellularsignal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol. 116(1): 135-145.
9. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. (2010). Axl is an essential epithelial-To-mesenchymal transitioninduced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 107(3): 1124-1129.
10. Goruppi S, Ruaro E, Varnum B, Schneider C. (1999). Gas6-mediated survival in NIH3T3 cells activates stress signaling cascade and is independent of Ras. Oncogene. 18(29): 4224-4236.
11. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, Dahlbäck B. (2009). Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 15(14): 4742-4749.
12. Gustafsson A, Boström AK, Ljungberg B, Axelson H, Dahlbäck B. (2009). Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS One. 4(10): e7575.
13. Hafizi S, Alindri F, Karlsson R, Dahlbäck B. (2002). Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. Biochem Biophys Res Commun. 299(5): 793-800.
14. Hafizi S, Dahlbäck B. (2006). Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 273(23): 5231-5244.
15. Han J, Tian R, Yong B, Luo C, Tan P, Shen J, Peng T. (2013). Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. Biochem Biophys Res Commun. 435(3): 493-500.
16. Harada K, Miyake H, Kumano M, Fujisawa M. (2013). Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2. Br J Cancer. 109(9): 2389-2395.
17. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, LesovoyV, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Global ARCC Trial. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 356: 2271-2281.
18. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF, Bartram CR. (1991). A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene. 6: 2113-2120.
19. Kanesvaran R, Tan MH. (2014). Targeted therapy for renal cell carcinoma: the next lap. J Carcinog. 13: 3.
20. Konishi A, Aizawa T, Mohan A, Korshunov VA, Berk BC. (2004). Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells. J Biol Chem. 279(27): 28766-28770.
21. Ku BM, Kim SJ, Kim N, Hong D, Choi YB, Lee SH, Gong YD, Kim SY. (2014). Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models. J Cancer Res Clin Oncol. 140(5): 757-767.
22. Lai C, Gore M, Lemke G. (1994). Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene. 9: 2567-2578.
23. Leconet W, Larbouret C, Chardès T, Thomas G, Neiveyans M, Busson M, Jarlier M, Radosevic-Robin N, Pugnière M, Bernex F, Penault-Llorca F, Pasquet JM, Pèlegrin A, Robert B. (2013). Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene. 33(47): 5405-5414.
24. Lemke G. (2013). Biology of the TAM receptors. Cold Spring Harb Perspect Biol. 5(11): a009076.
25. Liu R, GongM, Li X, Zhou Y, GaoW, TulpuleA, Chaudhary PM, Jung J, Gill PS. (2010). Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma. Blood. 116(2): 297-305.
26. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-Time quantitative PCR and the 2 (-delta deltaC(T)) method. Methods. 25(4): 402-408.
27. Melaragno MG, Fridell YW, Berk BC. (1999). The Gas6/Axl system: a novel regulator of vascular cell function. Trends Cardiovasc Med. 9(8): 250-253.
28. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. (2002). Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res. 8: 361-367.
29. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A. RECORD-1 Study Group. (2010). Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 116: 4256-4265.
30. Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI. (2013). Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomized phase 3 trial. Lancet Oncol. 14: 552-562.
31. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356: 115-124.
32. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa. 3rd R, Le Beau MM, Earp HS, Liu ET. (1991). axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 11(10): 5016-5031.
33. Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ, Fletcher JA. (2011). AXL regulates mesothelioma proliferation and invasiveness. Oncogene. 30(14): 1643-1652.
34. Paccez JD, Vasques GJ, Correa RG, Vasconcellos JF, Duncan K, Gu X, Bhasin M, Libermann TA, Zerbini LF. (2013). The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene. 32(6): 689-698.
35. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. (2007). TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 131(6): 1124-1136.
36. Sheridan C. (2013). First Axl inhibitor enters clinical trials. Nat Biotechnol. 31(9): 775-776.
37. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, Wu CW. (2005). Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 7(12): 1058-1064.
38. Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. CA Cancer J Clin. 63(1): 11-30.
39. Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH, Zarba JJ, Gladkov OA, Lee E, Szczylik C, McCann L, Rubin SD, Chen M, Davis ID. (2013). A randomized, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 49: 1287-1296.
40. Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY, Lin WC. (2002). Clinical significance of AXL kinase family in gastric cancer. Anticancer Res. 22(2B): 1071-1078.
41. Yanagita M, Arai H, Nakano T, Ohashi K, Mizuno K, Fukatsu A, Doi T, Kita T. (2001). Gas6 induces mesangial cell proliferation via latent transcription factor STAT3. J Biol Chem. 276(45): 42364-42369.
42. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y, Pei L. (2010). An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene. 29(38): 5254-5264.
43. Zhang Y, Li N, Chen Q, Yan K, Liu Z, Zhang X, Liu P, Chen Y, Han D. (2013). Breakdown of immune homeostasis in the testis of mice lacking Tyro3, Axl and Mer receptor tyrosine kinases. Immunol Cell Biol. 91(6): 416-426.
44. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai I, Daub H, Kéri G, Ullrich A. (2008). AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res. 68(6): 1905-1915.
45. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. (2012). Activation of the AXL kinase causes resistance to EGFR-Targeted therapy in lung cancer. Nat Genet. 44(8): 852-860.